Research and Markets: Breast Cancer: Vaccines and Therapeutic Antibodies - Findings on More than 30 Candidate Therapies, Including 22 Vaccines and 11 Antibodies

Research and Markets (http://www.researchandmarkets.com/research/1de254/breast_cancer_vac) has announced the addition of the "Breast Cancer: Vaccines and Therapeutic Antibodies - 2010" report to their offering.

The breast cancer immunotherapy pipeline is showing rapid development. This report presents findings on more than 30 candidate therapies, including 22 vaccines and 11 antibodies.

Drugs used to treat breast cancer fall into three main groups: hormonal blockers, chemotherapeutic agents and targeted antibodies. Hormonal blocking agents include drugs such as tamoxifen and the aromatase inhibitors (e.g. anastrozole, letrozole), and chemotherapeutic drugs include alkylating agents (e.g. cyclophosphamide), anthracycline antibiotics (e.g. doxorubicin) and taxanes (e.g. docetaxel). Targeted antibodies include trastuzumab, which blocks the HER-2 receptor. While these drugs provide important treatment options for patients, their limitations (drug resistance, poor efficacy and side effects) have focused efforts on developing safer and more effective targeted therapies. Currently, the greatest growth in this field is in the development of breast cancer immunotherapies; vaccines and therapeutic antibodies.

This report presents a comprehensive review of the breast cancer immunotherapy pipeline, covering new candidate vaccines and antibodies. Currently, there are more than 20 candidate breast cancer vaccines in the pipeline. These include selective candidates developed to target breast cancer and others evaluated against a number of cancer types, including breast cancer. This report also covers 11 antibodies, some of which are new molecules developed to selectively target breast cancer and others, that are being evaluated for a number of cancers, including breast cancer.

These candidate breast cancer vaccines and antibodies target 17 cancer antigens or antibody targets, and are being taken forward by 30 companies. Of these, 23 (77%) are small and medium-sized organisations or groups, and seven are major multinational pharmaceutical companies. Of these candidates, two, three, one, eight, seven, seven and six are Approved or at Phase III, Phase II/III, Phase II, Phase I/II, Phase I or at the preclinical stage, respectively. This report provides a comprehensive review on the breast cancer immunotherapy pipeline and presents summary clinical findings (pre-clinical to Phase III) on the candidates presented.

Key Topics Covered:

Chapter 1 Background

Chapter 2 Breast Cancer Immunotherapy Strategies

Chapter 3 Approved

Chapter 4 Phase III

Chapter 5 Phase II/III

Chapter 6 Phase II

Chapter 7 Phase I/II

Chapter 8 Phase I

Chapter 9 Preclinical

Chapter 10 Discussion

For more information visit http://www.researchandmarkets.com/research/1de254/breast_cancer_vac